Infectious mononucleosis in older adults

Author: Peter Axelrod, Albert J. Finestone
Date: Dec, 1990

Although infectious mononucleosis is readily diagnosed in adolescents and young adults, it frequently presents a diagnostic challenge when it occurs in older adults. This article presents a case of infectious mononucleosis involving a 70-year-old woman and reviews the clinical and laboratory features of infectious mononucleosis in adults over age 40. The spectrum of atypical presentations of the disease among older adults is also discussed.

Illustrative Case

A 70-year-old woman was admitted to the hospital with fever, pharyngitis, back pain and dehydration. She had been in good health until two and one-half weeks before admission, when she noted left-sided lower back pain while playing tennis. Shortly thereafter, she developed daily fever (to 38.3 [degrees] C [ 101 [degrees] F]), sore throat, diffuse myalgias, right frontal headache, mild right upper quadrant and epigastric pain, and nausea.

The patient denied exposure to animals, seafood or persons with tuberculosis, and she had received no blood transfusions. One month before admission, she had been exposed briefly to a relative with infectious mononucleosis. She had a history of childhood tonsillectomy, colonic polypectomy 30 years prior to admission, irritable bowel syndrome and osteoarthritis. Medications included conjugated estrogens (discontinued four weeks before the onset of symptoms), butalbital, aspirin and diazepam.

The initial physical examination revealed mild exudative pharyngitis and palpable 1- to 2-cm lymph nodes in the posterior cervical, submandibular, axillary and inguinal regions. The liver edge was palpable 2 cm below the right costal margin.

Laboratory tests at this time showed a white blood cell count of 3,200 per mm[.sup.3] (3.2 x 10[.sup.9] per L), with 35 percent (0.35) segmented neutrophils, 18 percent (0.18) band cells, 36 percent (0.36) lymphocytes, 4 percent (0.04) reactive lymphocytes, 5 percent (0.05) monocytes and 1 percent (0.01) eosinophils. The hemoglobin level was 13.9 g per dL (139 g per L); hematocrit was 42.1 percent (0.42), and platelet count was 139,000 per mm[.sup.3] (139 x 10[.sup.9] per L).

Other laboratory values included serum creatinine, 0.9 mg per dL (69 [mu]mol per L); bilirubin, 0.4 mg per dL (7 [mu]mol per L); lactate dehydrogenase, 416 U per L (416 U per L); aspartate aminotransferase (AST), 339 U per L (339 U per L); alanine aminotransferase ALT), 390 U per L (390 U per L); alkaline phosphatase, 524 U per L (524 U per L), and amylase, 113 U per L (113 U per L). Tests for hepatitis B surface antigen, hepatitis A IgM antibody and cytomegalovirus antibody gave negative results. A slide test for heterophil antibody was positive. IgM and IgG antibodies to the Epstein-Barr virus capsid were detected.

During the next two weeks, anorexia, fever, headache and fatigue persisted and back pain increased. The patient was then admitted to the hospital. Exudative pharyngitis had worsened, and there was evidence of dehydration. On admission, the white blood cell count was 11,500 per mm[.sup.3] (11.5 x 10[.sup.9] per L), with 15 percent (0.15) segmented neutrophils, 7 percent (0.07) band cells, 53 percent (0.53) lymphocytes, 10 percent (0.10) atypical lymphocytes, 11 percent (0.11) monocytes, 3 percent (0.03) basophils and 1 percent (0.01) eosinophils; the platelet count was 270,000 per mm[.sup.3] (270 x 10[.sup.9] per L). Lactate dehydrogenase had increased to 456 U per L (456 U per L), and alkaline phosphatase to 889 U per L (889 U per L). Urinalysis and chest radiograph were normal; lumbosacral spine radiographs showed osteoarthritis. A throat culture yielded many beta-hemolytic non-group A streptococci. Intravenous fluids and erythromycin were administered. The patient was discharged in improved condition after six days.

COMMENT

Because of the patient's age and localized back pain, the minor degree of lymphocytosis and small number of atypical lymphocytes, and the significant elevation of liver enzymes, infectious mononucleosis was initially not considered as a diagnosis in this case. The diagnosis was established, however, before unnecessary antibiotics were given and diagnostic tests for "fever of unknown origin" were carried out. The significance of the patient's exposure to a relative with infectious mononucleosis is unclear.

Age and Immune Response

From 80 to 90 percent of infectious mononucleosis cases are caused by the Epstein-Barrvirus. (1-3) Epstein-Barr virus is a member of the herpesvirus group that infects at least 95 percent of the world's population. (4,5) Epstein-Barr virus causes an initial systemic (primary) infection and then becomes latent in the B lymphocytes and lymphoid tissue of the host. (6) Latent-infection persists for the lifetime of the host.

Most infected persons are asymptomatic at the time of primary infection and can be identified only by serologic testing. (6) However, the likelihood of symptomatic primary infectious mononucleosis has been found to depend on the age at which the primary infection occurs. In the United States and Great Britain, seroconversion occurs in about one-half of children before the age of five, (7,8) but symptomatic infectious mononucleosis is rare in this age group. Clinically apparent infectious mononucleosis is much more common among adolescents who seroconvert. (6) It seems likely that the difference in clinical expression of infection in these two age groups reflects a fundamental difference in the way their immune systems react to Epstein-Barr virus, but this remains to be clarified.

The ratio of apparent to inapparent primary infection in older adults is unknown. Serologic surveys have shown that between 3 and 10 percent of adults over age 60 lack Epstein-Barr virus antibodies and are presumably at risk for primary Epstein-Barr virus infection and infectious mononucleosis. (9) In a small prospective study, (10) Epstein-Barr virus seroconversion occurred in six patients in a home for the aged, but none of these patients were symptomatic. Larger studies have not been performed.

Older adults have a diminished ability to inhibit the activity of latent Epstein-Barr virus if they are chronically infected. In latent infection, Epstein-Barr virus replication and synthetic metabolism are normally inhibited by the host's cellular immune system. (11,12) In situations in which host cellular immunity is decreased, viral replication and protein synthesis increase. The host responds by producing increased antibodies to Epstein-Barr virus proteins. This response has been demonstrated in patients with cellular immune deficiencies (e.g., malignancy, renal transplantation). (13,14)

Numerous studies (15-18) have shown that Epstein-Barr virus antibodies increase significantly with age, presumably reflecting a deteriorating ability of the cellular immune system to "handle" the virus. No convincing evidence shows that this putative loss of control over latent Epstein-Barr virus in the older adult has any significant clinical consequences. It is not clear whether the "atypical" manifestations of acute infectious mononucleosis in older adults are a reflection of altered immune responsiveness to Epstein-Barr virus in this age group.

Incidence in Older Adults

Infectious mononucleosis is an uncommon illness in persons over 40 years of age; it occurs most frequently in adolescence and early adulthood. Age-specific incidence rates of heterophil-positive infectious mononucleosis, derived from two studies of large urban populations, are shown in Table 1. (19,20) The incidence rate peaks between ages 15 and 19 (345 to 671 per 100,000 population per year) and then declines steadily. The incidence in persons over age 35 is only two to four per 100,000 per year. The peak incidence occurs at a slightly later age in males (18 to 23 years) than in females (15 to 16 years), but by age 35 no gender difference in incidence rates is seen.

Clinical and Laboratory Features

The clinical features of infectious mononucleosis in persons under age 35 and in those over age 40 are compared in Table 2 [omitted]. (9,21-40) These data may be biased, however, because of a tendency to include unusual cases in case reports and case series. The prevalence of fever and rash is similar in the two age groups. Fever is the most common symptom in both age groups, occurring in 89 percent of adolescents and in 95 percent of patients over age 40. However, in a direct comparison of adolescents and patients over age 40 at the same institution, one study (21) found the duration of fever to be significantly longer in the older patients (median duration: 13 versus seven days).

Older adults have lower rates of pharyngitis, lymphadenopathy and splenomegaly, signs and symptoms that are typical of infectious mononucleosis in the adolescent. In contrast, older adults have substantially higher rates of hepatomegaly and jaundice.

1 Horwitz CA, Henle K Henle G, et al. Heterophil-negative infectious mononucleosis and mononucleosis-like illnesses. Laboratory confirmation of 43 cases. Am J Med 1977;63: 947-57.

2. Klemola E, Von Essen R, Henle G, Henle W. Infectious-mononucleosis-like disease with negative heterophil agglutination test. Clinical features in relation to Epstein-Barr virus and cytomegalovirus antibodies. J Infect Dis 1970;121:608-14.

3. Nikoskelainen J, Leikola J, Klemola E. IgM antibodies specific for Epstein-Barr virus in infectious mononucleosis without heterophil antibodies. Br Med J 1974;4:72-5.

4. Henle W, Henle G, Zajac BA, Pearson G, Waubke R, Scriba M. Differential reactivity of human serums with early antigens induced by Epstein-Barr virus. Science 1970;169:188-90.

5. Henle C, Henle K Clifford P, et al. Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups. J Natl Cancer Inst 1969;43:1147-57.

6. Schooley RT, Dolin R. Epstein-Barr virus (infectious mononucleosis). In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and practice of infectious diseases. 2d ed. New York: Wiley, 1985:971-81.

7. Pereira MS, Blake JM, Macrae AD. EB virus antibody at different ages. Br Med J 1969; 4:526-7.

8. Porter DD, Wimberly I, Benyesh-Melnick M. Prevalence of antibodies to EB virus and other herpesviruses. JAMA 1969;208:1675-9.

9. Schmader KE, van der Horst CM, Klotman ME. Epstein-Barr virus and the elderly host. Rev Infect Dis 1989; 11: 64-73.

10. Homsleth A, Siggaard-Andersen J, Hjort L. Epidemiology of herpesvirus and respiratory virus infections. Part 1. Serologic findings. Geriatrics 1975;30(8):61-8.

11. Thorley-Lawson DA, Chess L, Strominger JL. Suppression of in vitro Epstein-Barr virus infection. A new role for adult human T lymphocytes. J Exp Med 1977; 146:495-508.

12. Schooley RT, Haynes BF, Grouse J, Payling-Wright C, Fauci AS, Dolin R. Development of suppressor T-lymphocytes for Epstein-Barr virus-induced B-lymphocyte outgrowth during acute infectious mononucleosis: assessment by two quantitative systems. Blood 1981;57:510-7.

13. Henle K Henle G. Epstein-Barr virus-specific serology in immunologically compromised individuals. Cancer Res 1981;41(11 Pt 1):4222-5.

14. Cheeseman SH, Henle K Rubin RH, et al. Epstein-Barr virus infection in renal transplant recipients. Effects of antithymocyte globulin and interferon. Ann Intern Med 1980; 93:39-42.

15. Glaser R, Strain EC, Tarr KL, Holliday JE, Donnerberg RL, Kieclot-Glaser JK. Changes in Epstein-Barr virus antibody titers associated with aging. Proc Soc Exp Biol Med 1985; 179:352-5.

16. Sumaya CV, Henle K Henle G, Smith MH, LeBlanc D. Seroepidemiologic study of Epstein-Barr virus infections in a rural community. J Infect Dis 1975; 131:403-8.

17. Gurtsevich V, Le Riverend E, Riuz R. Seroepidemiologic study of Epstein-Barr virus infectivity in a healthy Cuban population. Neoplasma 1979;26:677-83.

18. Sohier R, Freund RJ, de The G, Day NE, Geser A, Denhaut G. Seroepidemiology of herpesvirus type Epstein-Barr in blood donors from communities around Lyon. Am J Epidemiol 1974;99:414-24.

19. Henke CE, Kurland LT, Elveback LR. Infectious mononucleosis in Rochester, Minnesota, 1950 through 1969. Am J Epidemiol 1973; 98:483-90.

20. Heath CW Jr, Brodsky AL, Potolsky Al. Infectious mononucleosis in a general population. Am J Epidemiol 1972;95:46-52.

21. Halevy J, Ash S. Infectious mononucleosis in hospitalized patients over forty years of age. Am J Med Sci 1988;295:122-4.

22. Finkel M, Parker GW, Fanselau HA. The hepatitis of infectious mononucleosis: experience with 235 cases. Milit Med 1964;129:533-8.

23. Rosalki SB, Jones TG, Verney AF. Transaminase and liver-function studies in infectious mononucleosis. Br Med J 1960;5177:929-32.

24. Horwitz CA, Henle K Henle G, Schapiro R, Borken S, Bundtzen R. Infectious mononucleosis in patients aged 40 to 72 years: report of 27 cases, including 3 without heterophilantibody responses. Medicine 1983;62:256-62.

25. Carter JW, Edson RS, Kennedy CC. Infectious mononucleosis in the older patient. Mayo Clin Proc 1978;53:146-50.

26. Ginsburg AD, Ginsburg JC. Infectious mononucleosis in older patients. Can Med Assoc J 1982;127:1103-4.

27. Pickens S, Murdock JM. Infectious mononucleosis in the elderly. Age Ageing 1979; 8(2):93-5.

28. Horwitz CA, Henle K Henle G, et al. Clinical and laboratory evaluation of elderly patients with heterophil-antibody positive infectious mononucleosis. Report of seven patients, ages 40 to 78. Am J Med 1976;61:333-9.

29. Shapiro CM, Horwitz H. Infectious mononucleosis in the aged. Ann Intern Med 1959; 51:1092-7.

30. McKendrick MW, Geddes AM, Edwards JM. Atypical infectious mononucleosis in the elderly. Br Med J 1979;2:970.

31. Zahavi J, Seligsohn U. Unusual course of infectious mononucleosis. JAMA 1967,200:1181-3.

32. Corr WP. Infectious mononucleosis in the elderly. JAMA 1966; 195:1158.

33. Hadnagy C. Infectious mononucleosis in the case of two elderly (80 and 57 years old age) patients. Aktuel Gerontol 1978;8:153-8.

34. Hehlmann R, Walther B, Zollner N, Wolf H, Deinhart F, Schmid M. Fatal lymphoproliferation and acute monocytic leukemia-like disease following infectious mononucleosis in the elderly. Klin Wochenschr 1981;59:477-83.

35. Acikalin T, Akdamar K. Infectious mononucleosis in the elderly. J La State Med Soc 1980; 132:1-3.

36. Fitz-Hugh T Jr. Acute infectious mononucleosis in a 64 year old woman. Blood 1957;12: 398-9.

37. Otternan LA, Greipp PR, Ruiz-Arguelles GJ, Banks PM, Li CY, Katzmann JA. Infectious mononucleosis mimicking a B cell immunoblastic lymphoma associated with an abnormality in regulatory T cells. Am J Med 1985; 78:885-90.

38. Krause JR, Kaplan SS. Bone marrow findings in infectious mononucleosis and mononucleosis-like diseases- in the older adult. Scand J Haematol 1982;28:15-22.

39. Jones J, Gardner K Newman T. Severe optic neuritis in infectious mononucleosis. Ann Emerg Med 1988; 17:361-4.

40. Corr WP Jr. Infectious mononucleosis in the aging. JAMA 1967;202:173.

TABLE 1Age-Specific Incidence of Infectious Mononucleosis (19,20) Cases per 100,000Age (years) population per year0-4 3-315-14 43-6315-19 345-67120-24 123-32725-29 25-10230-34 10-32>34 2-4

PETER AXELROD, M. D. is assistant professor of medicine in the section of infectious diseases at Temple University School of Medicine, Philadelphia. Dr. Axelrod is a graduate of Yale University School of Medicine, New Haven, Conn., and completed an internship and a residency at Temple University Hospital.

ALBERT J. FINESTONE, M. D. is professor of medicine and associate dean in the Office for Continuing Medical Education at Temple University School of Medicine, where he earned his medical degree. Dr. Finestone completed an internship and residency in internal medicine at Temple University Hospital and served a fellowship in pathology at Georgetown University School of Medicine, Washington, D.C.

COPYRIGHT 1990 American Academy of Family PhysiciansCOPYRIGHT 2004 Gale Group

 
© 2006, DrPlace.com, All Rights Reserved.